

MARDI 16 SEPTEMBRE 2025

MAS, Paris 13e

10 rue des terres au curé



LA PROTÉOMIQUE
À LARGE ÉCHELLE
POUR L'ÉTUDE DU MICRO-
ENVIRONNEMENT TUMORAL


GROUPE MICROENVIRONNEMENT TUMORAL

SPATIAL PROTEOMIC Mass Spectrometry Imaging

Hélène Cazier and Rémy Nicolle



Decipher the tumoral microenvironnement Toward spatial proteomic approaches




Bulk approaches

Homogenized molecular information

High coverage information with PTMs information

“Quick and cheap” sample prep
Specialized equipment

DECIPHER THE TUMORAL MICROENVIRONNEMENT



Spatial approaches

Regional level heterogeneity

Low coverage information

Specialized equipment
Time consuming sample prep




Single Cell approaches

Cellular level heterogeneity


Full repertoire molecular state

Current cost are restricting


SPATIAL OMICS APPROACHES



TRANSCRIPTOMICS



METABOLOMICS AND LIPIDOMICS




PROTEOMICS



Towards spatial proteomics

Spatial proteomics approaches

DECIPHER THE TUMORAL MICROENVIRONNEMENT



Why proteins ?

Proteins are the functional
molecules carrying most
cellular functions

Post-translational
modifications critical for
activity, localization and
interactions

Many biomarkers and drug
targets are actually proteins

TARGETED PROTEOMIC

Immunofluorescence

IHC multiplex

CyTOF
MALDI HiPLEX-IHC

UNTARGETED PROTEOMIC

Mass spectrometry
Imaging




Top down (Protein
Intact)

Bottom up (digested
peptide)




Towards spatial proteomics in mass spectrometry

Samples and methods



Protocols for sample conservation

FFPE tissues
= Formalin Fixed Para fin embedding tissue



Fresh frozen tissues
(snap frozen : nitrogen/isopentane, stored at -80°C)



Samples treatments on slides




Delipidation (chloroform)
Desalting (ammonium sulfate)
Antigenic retrieval



Derivatization : aromatic ring or charge addition
On tissue digestion (Trypsin, PNGase ...)


Towards spatial proteomics in mass spectrometry

MALDI Mass spectrometry imaging



Towards spatial proteomics in mass spectrometry


MALDI Mass spectrometry imaging





Towards spatial proteomics in mass spectrometry



Software and important parameters






Towards spatial proteomics in mass spectrometry

Analytical challenge and imaging data integration



1655.822 m/z \pm 0.118 Da 0% 63% 240%



1655.805 m/z \pm 0.139 Da 0% 63% 291%

Projet MAIA : 30 slices of cHCC-CCA

Acquisition : 100 μ m on whole slice

Raw = 360 Go

Processed data = 1,656 To

Scan HES + IHC = 665 Go

Mean of 39 000 pixel/ slices
1,17 millions of pixels

Projet CHRIS : 50 slices of ADK

Acquisition : 50 μ m on whole slice

Raw = 2,5 To

Processed data = 7 To

Scan HES = 150 Go

Mean of 120 000 pixel/ slices
6 millions of pixels

61 slices of lung

Acquisition : 35 μ m on partial slice

Raw = 482 Go


Processed data = 677 Go

Scan HES = 100 Go

Mean of 26 000 pixel/ slices
1,59 millions of pixels


Towards spatial proteomics in mass spectrometry

MALDI Mass spectrometry imaging



Towards spatial proteomics in mass spectrometry



Microdissection based on MALDI imaging





Towards spatial proteomics in mass spectrometry

Integration of MALDI-MSI in pathology routine




Bioinformatics needed to combine all of those data

Towards spatial proteomics in mass spectrometry

cHCC-CCA analysis with mass spectrometry

Hepatocytic and cholangiocytic contingent sometimes associated
with a "intermediate" contingent within the same tumor

Primary Liver Carcinomas (PLC)



BETTER CHARACTERIZATION OF MIXED TUMORS FOR IMPROVED DIAGNOSIS AND TREATMENT OF cHCC-CCA TUMORS

Towards spatial proteomics in mass spectrometry


cHCC-CCA analysis with mass spectrometry



Segmentation
performed on
MALDI MSI data



Pathologist
annotations on
HES



- HCC
- iCCA
- Intermediate
- Fibrosis
- Microvascular invasion


MORE HETEROGENEITY BASED ON MOLECULAR INFORMATION THAN ON MORPHOLOGY

Towards spatial proteomics in mass spectrometry

cHCC-CCA analysis with mass spectrometry


HES with pathologist annotations

*MALDI MSI segmentation with
microdissected ROIs annotations*




Hepatocholangiocarcinoma

MALDI imaging analysis is correlated with LC/MS-MS proteomic rather than morphology for CCA and intermediate contingents






Pancreatic adenocarcinoma



Frequent late-
stage diagnosis

High invasive
potential

Broad
chemoresistance



5 year
survival


510 992 cases diagnosed worldwide in 2022
In France **4 500** in 1997, **15 991** in 2023



A growing burden

Projected Cancer-related Deaths

+1,6% per year in men
+2,1% per year in women



2040 projections :


11% of all cancer-related deaths



High level of heterogeneity

Inter-tumor heterogeneity

- Long survivors
- 10% to 30% initial responders to chemo
- ...



Balachandran et al. Nature 2017;551:512–516.


Intra-tumor heterogeneity



Tumor epithelium


Stroma

Molecular classifications



Bailey et al , Function 2023

Moffitt et al
Collisson et al
Chan-Seng-Yue et al
Bailey et al




Puleo, Nicolle et al,
Gastroenterology 2018




AI on histology to *paint* PDAC: PACpAIInt


Transcriptome-based subtyping




Transfer to histology




Basal



Classical





Stroma



Inactive

Active

451 patients, 6.3 million tiles








Morphomolecular patterns: associate the transcriptome to histology



Pr. Jerome Cros Julien de
Martino




Ex: 1 slide, 3 different histological patterns



Area 1
Morphology 1


Area 2
Morphology 2



Area 3
Morphology 3




407 matched
transcriptome &
morphology

100 patients
1 019 tissue blocks





TFF1



CLDN18


Marker genes of *Classical* tumor phenotype




Training Models : Multiple Instance Learning

Delineate morpho-molecular patterns


Stromas



ROI
n=407




Tile-level
Unsupervised analysis




12 Patterns



Tumor : classical




Tumor: Basal-like



Tumor: inflammatory "Basal"



Lymphoid pattern








Spatial distribution and co-occurrence

Trained on 407 small ROI









Projected on 1'019 whole tumor blocks



Lymphoid
dense areas



n = 1 019







What makes up a CD8 T cell-compliant stroma?




C. JEAN





Collagen




IHC CD8






Lymphoid-compliant stroma






40 PDAC

CD8-compliant stroma found in every tumor around CD8 infiltration





Characterize CD8-related stroma



CD8 excluding stroma

COL1A1/2, COL11A1, COL12A1,
COL5A1, Fibronectin

CD8 infiltrated stroma

COL4A3/4, COL19A1, Reelin



Towards spatial proteomics in mass spectrometry

To conclude ...

✓ Molecular heterogeneity are more important than their histological heterogeneity






✓ We have demonstrated the usefulness of mass spectrometry imaging to highlight intra-tumoral heterogeneity using proteomic approaches.

✓ Mass spectrometry imaging identifies novel diagnostic and biological biomarkers

✓ MALDI-MSI combined with targeted microdissected areas analyzed by LC-MS/MS = optimal method for FFPE tissues

✓ Bioinformatics is essential for big data analysis, as it provides the computational tools and algorithms needed to process, integrate, and interpret complex biological datasets





Service de pathologie

Valérie Paradis
Aurélie Beaufrere
Alexandre Sayadi
Miguel Albuquerque
Nathalie Colnot

Equipe GenetheX

Audrey Beaufiles
Camille Pignolet
Rémy Nicole

Plateforme Protéomique de Necker

Joanna Lipecka
Chiara Guerrera

Equipe MicMac
Samira Laouirem
Adel Hammoutene
Etienne Becht

Plateforme iMAP

Ghalia Ben Ghedifa
Rovelyne Pissa
Meriem Marref
Ihsan Grichi
Arnaud Senecaut
Elia Gigante